The ART1 Knockout LoVo Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human LoVo colorectal adenocarcinoma cell line. This heterogeneous pool of edited cells carries targeted disruption at the ART1 locus, generating a loss-of-function model for the arginine-specific ADP-ribosyltransferase ART1. Unlike monoclonal knockout cell lines, the polyclonal format reflects the diversity of editing outcomes while ensuring robust average gene disruption across the population.
The parental LoVo cell line is a well-established model of human colorectal adenocarcinoma, characterized by microsatellite instability and mutations in the tumor suppressors APC and p53, as well as the oncogene KRAS. These genetic features recapitulate a subset of colorectal cancers with defective DNA mismatch repair and aberrant signaling pathways. As an intestinal epithelial cell line, LoVo provides a physiologically relevant host for studying colorectal cancer biology and therapeutic responses.
ART1 encodes an arginine-specific mono-ADP-ribosyltransferase that catalyzes the transfer of ADP-ribose from the co-substrate NAD+ to arginine residues on target proteins. This enzymatic activity is regulated by the pro-inflammatory cytokines IFN-?? and TNF-??, which upregulate ART1 expression. Known downstream substrates include histone H3, integrin ??7, and the purinergic P2X7 receptor. The modification is dynamically reversed by ADP-ribosylarginine hydrolase. Through these molecular interactions, ART1 modulates immune cell recruitment, cell-matrix adhesion, and inflammatory signal transduction.
In the LoVo colorectal cancer background, ART1 knockout disrupts the ADP-ribosylation network, potentially altering the post-translational modification landscape and downstream signaling events. This model is particularly valuable for examining how loss of ART1-mediated arginine modification influences tumor cell migration, invasion, and apoptosis. Moreover, given the microsatellite instability of LoVo cells, these knockout cells offer a platform to study the intersection between defective DNA repair, immune evasion, and ADP-ribosylation-dependent immune regulation.
Researchers deploy these ART1 knockout polyclonal cells in a variety of functional studies, including migration and invasion assays to evaluate metastatic potential, apoptosis assays to assess cell death pathways, and cytokine profiling to measure immune-modulatory outputs. Standard characterization involves RT-qPCR for ART1 transcript levels and western blotting to detect global or substrate-specific ADP-ribosylation changes. Immunofluorescence enables visualization of target protein localization. The cells are also suited for inhibitor screening campaigns targeting the ART1 active site. For further information, please contact Ascent Research.
